

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>JP MORGAN PARTNERS BHCA LP</u> (Last) (First) (Middle) C/O J.P. MORGAN PARTNERS, LLC 270 PARK AVENUE (Street) NEW YORK NY 10017 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/08/2007	3. Issuer Name and Ticker or Trading Symbol <u>Emergent BioSolutions Inc. [EBS]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) Member of 13(d) group	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	727,209	D ⁽¹⁾	
Common Stock	415,381	D ⁽²⁾	
Common Stock	94,399	D ⁽³⁾	
Common Stock	47,652	D ⁽⁴⁾	
Common Stock	13,689	D ⁽⁵⁾	
Common Stock	5,320	D ⁽⁶⁾	
Common Stock	33,714	D ⁽⁷⁾	
Common Stock	117,054	D ⁽⁸⁾	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

1. Name and Address of Reporting Person*
JP MORGAN PARTNERS BHCA LP
 (Last) (First) (Middle)
 C/O J.P. MORGAN PARTNERS, LLC
 270 PARK AVENUE
 (Street)
 NEW YORK NY 10017
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
JP MORGAN PARTNERS GLOBAL INVESTORS LP
 (Last) (First) (Middle)
 C/O J.P. MORGAN PARTNERS, LLC
 270 PARK AVENUE
 (Street)
 NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP](#)

(Last) (First) (Middle)

C/O J.P. MORGAN PARTNERS, LLC
270 PARK AVENUE

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[J P MORGAN PARTNERS GLOBAL INVESTORS A LP](#)

(Last) (First) (Middle)

C/O J.P. MORGAN PARTNERS, LLC
270 PARK AVENUE

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP](#)

(Last) (First) (Middle)

C/O J.P. MORGAN PARTNERS, LLC
270 PARK AVENUE

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[JP MORGAN PARTNERS GLOBAL INVESTORS SELLDOWN LLP](#)

(Last) (First) (Middle)

C/O J.P. MORGAN PARTNERS, LLC
270 PARK AVENUE

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[JP MORGAN PARTNERS GLOBAL INVESTORS SELLDOWN II L P](#)

(Last) (First) (Middle)

C/O J.P. MORGAN PARTNERS, LLC
270 PARK AVENUE

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[JPMP MASTER FUND MANAGER L P](#)

(Last) (First) (Middle)

C/O J.P. MORGAN PARTNERS, LLC
270 PARK AVENUE

(Street)
NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[JPMP GLOBAL INVESTORS L P](#)

(Last) (First) (Middle)

C/O J.P. MORGAN PARTNERS, LLC
270 PARK AVENUE

(Street)
NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[JPMP CAPITAL CORP](#)

(Last) (First) (Middle)

C/O J.P. MORGAN PARTNERS, LLC
270 PARK AVENUE

(Street)
NEW YORK NY 10017

(City) (State) (Zip)

Explanation of Responses:

1. See Exhibit 99.1.
2. The amount shown represents the beneficial ownership of the Issuer's securities owned by JPMP BHCA.
3. The amount shown represents the beneficial ownership of the Issuer's securities owned by J.P. Morgan Global.
4. The amount shown represents the beneficial ownership of the Issuer's securities owned by JPMP Cayman.
5. The amount shown represents the beneficial ownership of the Issuer's securities owned by JPMP Global A.
6. The amount shown represents the beneficial ownership of the Issuer's securities owned by JPMP Cayman II.
7. The amount shown represents the beneficial ownership of the Issuer's securities owned by JPMP Selldown.
8. The amount shown represents the beneficial ownership of the Issuer's securities owned by JPMP Selldown II.

[J.P. MORGAN PARTNERS \(BHCA\), L.P. By: JPMP Master Fund Manager, L.P., its general partner By: JPMP Capital Corp., its general partner By: /s/ John C. Wilmot Name: John C Wilmot Title: Managing Director](#) 03/08/2007

[J.P. MORGAN PARTNERS GLOBAL INVESTORS A, L.P. By: JPMP Global Investors, L.P., its general partner By: JPMP Capital Corp., its general partner By: /s/ John C. Wilmot Name: John C Wilmot Title: Managing Director](#) 03/08/2007

[J.P. MORGAN PARTNERS GLOBAL INVESTORS, L.P. By: JPMP Global Investors, L.P., its general partner By: JPMP Capital Corp., its general partner By: /s/ John C. Wilmot Name: John C Wilmot Title: Managing Director](#) 03/08/2007

[J.P. MORGAN PARTNERS GLOBAL INVESTORS \(CAYMAN\), L.P. By: JPMP Global Investors, L.P., its general partner By: JPMP](#) 03/08/2007

Capital Corp., its general partner By: s/s John C. Wilmot
Name: John C Wilmot Title: Managing Director
J.P. MORGAN PARTNERS GLOBAL INVESTORS (CAYMAN) II, L.P. By: JPMP
Global Investors, L.P., its general partner By: JPMP 03/08/2007
Capital Corp., its general partner By: /s/ John C. Wilmot
Name: John C Wilmot Title: Managing Director
J.P. MORGAN PARTNERS GLOBAL INVESTORS (SELLDOWN), L.P. By: JPMP
Global Investors, L.P., its general partner By: JPMP 03/08/2007
Capital Corp., its general partner By: /s/ John C. Wilmot
Name: John C Wilmot Title: Managing Director
J.P. MORGAN PARTNERS GLOBAL INVESTORS (SELLDOWN) II, L.P. By: JPMP
Global Investors, L.P., its general partner By: JPMP 03/08/2007
Capital Corp., its general partner By: /s/ John C. Wilmot
Name: John C Wilmot Title: Managing Director
JPMP MASTER FUND MANAGER, L.P. By: JPMP
Capital Corp., its general partner By: /s/ John C. Wilmot 03/08/2007
Name: John C Wilmot Title: Managing Director
JPMP GLOBAL INVESTORS, L.P. By: JPMP Capital Corp., its general partner By: /s/ John C. Wilmot 03/08/2007
Name: John C Wilmot Title: Managing Director
JPMP CAPITAL CORP. By: /s/ John C. Wilmot 03/08/2007
Name: John C Wilmot Title: Managing Director

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

JPMP BHCA/Emergent BioSolutions Inc. -

- (1) This Form 3 is being filed by:
- (i) J.P. Morgan Partners (BHCA), L.P. (“**JPMP BHCA**”),
 - (ii) J.P. Morgan Partners Global Investors, L.P. (“**J.P. Morgan Global**”),
 - (iii) J.P. Morgan Partners Global Investors A, L.P. (“**JPMP Global A**”),
 - (iv) J.P. Morgan Partners Global Investors (Cayman), L.P. (“**JPMP Cayman**”),
 - (v) J.P. Morgan Partners Global Investors (Cayman) II, L.P. (“**JPMP Cayman II**”),
 - (vi) J.P. Morgan Partners Global Investors (Selldown), L.P. (“**JPMP Selldown**”),
 - (vii) J.P. Morgan Partners Global Investors (Selldown) II, L.P. (“**JPMP Selldown II**” and together with J.P. Morgan Global, JPMP Global A, JPMP Cayman, JPMP Cayman II and JPMP Selldown, the “**Global Funds**”),
 - (viii) JPMP Master Fund Manager, L.P. (“**JPMP MFM**”), the general partner of JPMP BHCA,
 - (ix) JPMP Global Investors, L.P. (“**JPMP Global**”), the general partner of the Global Funds, and
 - (x) JPMP Capital Corp. (“**JPMP Capital**”, and together with JPMP BHCA, the Global Funds, JPMP MFM and JPMP Global, the “**Reporting Persons**”), the general partner of JPMP MFM and JPMP BHCA.

Each of JPMP Global and JPMP Capital may be deemed, pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “**Exchange Act**”) to beneficially own the shares held by the Global Funds. Each of JPMP MFM and JPMP Capital may be deemed, pursuant to Rule 13d-3 under the Exchange Act to beneficially own the shares held by the JPMP BHCA. The amount shown represents the beneficial ownership of the Issuer’s common stock held by the Reporting Persons as a group.

Name and Address of Reporting Person (1)	Designated Reported (1)	Date of Event Requiring Statement	Issuer, Name, Ticker or Trading Symbol	Title and Amount of Security
J.P. Morgan Partners (BHCA), L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	J.P. Morgan Partners (BHCA), L.P.	March 8, 2007	Emergent BioSolutions Inc. [EBS]	See Table I Row 2

J.P. Morgan Partners Global Investors, L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	J.P. Morgan Partners (BHCA), L.P.	March 8, 2007	Emergent BioSolutions Inc. [EBS]	See Table I Row 3
---	-----------------------------------	---------------	----------------------------------	-------------------

Name and Address of Reporting Person (1)	Designated Reported (1)	Date of Event Requiring Statement	Issuer, Name, Ticker or Trading Symbol	Title and Amount of Security
J.P. Morgan Partners Global Investors (Cayman), L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	J.P. Morgan Partners (BHCA), L.P.	March 8, 2007	Emergent BioSolutions Inc. [EBS]	See Table I Row 4

J.P. Morgan Partners Global Investors A, L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	J.P. Morgan Partners (BHCA), L.P.	March 8, 2007	Emergent BioSolutions Inc. [EBS]	See Table I Row 5
---	-----------------------------------	---------------	----------------------------------	-------------------

J.P. Morgan Partners Global Investors (Cayman) II, L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	J.P. Morgan Partners (BHCA), L.P.	March 8, 2007	Emergent BioSolutions Inc. [EBS]	See Table I Row 6
---	-----------------------------------	---------------	----------------------------------	-------------------

J.P. Morgan Partners Global Investors (Selldown), L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	J.P. Morgan Partners (BHCA), L.P.	March 8, 2007	Emergent BioSolutions Inc. [EBS]	See Table I Row 7
--	-----------------------------------	---------------	----------------------------------	-------------------

J.P. Morgan Partners Global Investors (Selldown) II, L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	J.P. Morgan Partners (BHCA), L.P.	March 8, 2007	Emergent BioSolutions Inc. [EBS]	See Table I Row 8
JPMP Master Fund Manager, L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	J.P. Morgan Partners (BHCA), L.P.	March 8, 2007	Emergent BioSolutions Inc. [EBS]	See Table I Row 2
JPMP Global Investors, L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	J.P. Morgan Partners (BHCA), L.P.	March 8, 2007	Emergent BioSolutions Inc. [EBS]	See Table I Row 3-8
JPMP Capital Corp. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	J.P. Morgan Partners (BHCA), L.P.	March 8, 2007	Emergent BioSolutions Inc. [EBS]	See Table I Row 1

Name and Address of Reporting Person (1)	Title of Derivative Securities and Amount of Securities Underlying Derivative Securities	Ownership Form: Direct (D) or Indirect (I)	Nature of Indirect Beneficial Ownership	Disclaims Pecuniary Interest
J.P. Morgan Partners (BHCA), L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	Not Applicable	D	Not Applicable	
J.P. Morgan Partners Global Investors, L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	Not Applicable	D	Not Applicable	
J.P. Morgan Partners Global Investors (Cayman), L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	Not Applicable	D	Not Applicable	
J.P. Morgan Partners Global Investors A, L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	Not Applicable	D	Not Applicable	
J.P. Morgan Partners Global Investors (Cayman) II, L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	Not Applicable	D	Not Applicable	
J.P. Morgan Partners Global Investors (Selldown), L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	Not Applicable	D	Not Applicable	
J.P. Morgan Partners Global Investors (Selldown) II, L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	Not Applicable	D	Not Applicable	
JPMP Master Fund Manager, L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	Not Applicable	I	See Explanatory Note 1 below	No

Name and Address of Reporting Person (1)	Title of Derivative Securities and Title and Amount of Securities Underlying Derivative Securities	Ownership Form: Direct (D) or Indirect (I)	Nature of Indirect Beneficial Ownership	Disclaims Pecuniary Interest
JPMP Global Investors, L.P. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	Not Applicable	I	See Explanatory Note 2 below	No
JPMP Capital Corp. c/o J.P. Morgan Partners, LLC 270 Park Avenue New York, New York 10017	Not Applicable	I	See Explanatory Note 3 below	No

Explanatory Note:

(1) The amounts shown in Table I in row 2 represents the beneficial ownership of the Issuer's securities held by JPMP BHCA, a portion of which may be attributable to JPMP MFM because it is the sole general partner of JPMP BHCA. The actual pro rata portion of such beneficial ownership that may be attributable to JPMP MFM is not readily determinable because it is subject to several variables, including the internal rate of return and vesting interest within JPMP BHCA. JPMP MFM disclaims such beneficial ownership except to the extent of its pecuniary interest.

(2) The amounts shown in Table I in row 3 through 8 represents the beneficial ownership of the Issuer's securities held by the Global Funds, a portion of which may be attributable to JPMP Global because it is the sole general partner of the Global Funds. The actual pro rata portion of such beneficial ownership that may be attributable to JPMP Global is not readily determinable because it is subject to several variables, including the internal rate of return and vesting interest within the Global Funds. JPMP Global disclaims beneficial ownership except to the extent of its pecuniary interest.

(3) The amounts shown in Table I in row 1 represents the beneficial ownership of the Issuer's securities held by the Reporting Persons, a portion of which may be attributable to JPMP Capital because it is the sole general partner of JPMP MFM and JPMP Global. The actual pro rata portion of such beneficial ownership that may be attributable to JPMP Capital is not readily determinable because it is subject to several variables, including the internal rate of return and vesting interest within the JPMP BHCA and the Global Funds. JPMP Capital disclaims such beneficial ownership except to the extent of its pecuniary interest.